(Q27970312)

2

0 references

A Tsirbas

3

0 references

P Tan

4

0 references

A Gajdatsy

5

0 references

D Selva

Differences in clinical profile and relapse rate of type 1 versus type 2 autoimmune pancreatitis

6

0 references

language of work or name

English

0 references

publication date

January 2015

0 references

published in

Eye

0 references

volume

29

0 references

issue

1

0 references

page(s)

122-8

0 references

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4289839

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4289839

Abnormal expression of CD20 on IgG4 plasma cells associated with IgG4-related lymphadenopathy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4289839

Recent advances in autoimmune pancreatitis: type 1 and type 2.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4289839

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4289839

Long-term outcomes of autoimmune pancreatitis: a multicentre, international analysis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4289839

Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4289839

Immunoglobulin G4-related sclerosing disease of the paranasal sinus

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4289839

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4289839

Recurrence of IgG4-related disease following treatment with rituximab

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4289839

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4289839

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4289839

Orbital inflammation with IgG4-positive plasma cells: manifestation of IgG4 systemic disease

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4289839

Monoclonal anti-CD20 antibodies: mechanisms of action and monitoring of biological effects

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4289839

Endocapillary proliferative glomerulonephritis with crescent formation and concurrent tubulointerstitial nephritis complicating retroperitoneal fibrosis with a high serum level of IgG4.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4289839

Management and preparedness for infusion and hypersensitivity reactions

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4289839

Metachronous extrapancreatic lesions in autoimmune pancreatitis.

29 September 2017

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2014.251

High prevalence of IgG4-related lymphoplasmacytic infiltrative disorder in 25 patients with orbital inflammation: a retrospective case series.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2014.251

Immunoglobulin G4 (IgG4)-positive or -negative ocular adnexal benign lymphoid lesions in relation to systemic involvement.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2014.251

Clinicopathological features of IgG4-related disease complicated with orbital involvement.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2014.251

Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2014.251

Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2014.251

Abnormal anatomy of the superficial branch of the radial nerve

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2014.251

Rituximab therapy for refractory biliary strictures in immunoglobulin G4-associated cholangitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2014.251

Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4-related systemic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2014.251

Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: An open-label extension analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2014.251

Successful use of rituximab in a young patient with immunoglobulin G4-related disease and refractory scleritis.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4289839

27 November 2018

1 reference

12 December 2020

Treatment approaches to IgG4-related systemic disease

1 reference

12 December 2020

Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials

1 reference

12 December 2020

Ocular adnexal IgG4-related disease has uniform clinicopathology

1 reference

12 December 2020

Orbital inflammation in IgG4-related sclerosing disease

1 reference

12 December 2020

Evidence of follicular T-cell implication in a case of IgG4-related systemic disease with interstitial nephritis.

1 reference

12 December 2020

Prevalence and distribution of extrapancreatic lesions complicating autoimmune pancreatitis

1 reference

12 December 2020

Rituximab for the treatment of IgG4-related disease: lessons from 10 consecutive patients

1 reference

12 December 2020

Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011

1 reference

12 December 2020

The successful treatment of IgG4-positive colitis with adalimumab in a patient with IgG4-related sclerosing disease--a new subtype of aggressive colitis?

1 reference

12 December 2020

Successful use of rituximab in a young patient with immunoglobulin G4-related disease and refractory scleritis

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2014.251

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1038/EYE.2014.251

1 reference

Dimensions Publication ID

1347452

1022879515

0 references

1347452

1 reference

1 reference

1 reference